GeneDx Holdings (WGS) stock plummeted 9.41% in the pre-market trading on Tuesday, despite the company reporting strong preliminary financial results for the fourth quarter and full year of 2024.
The genetic testing company said it expects to report revenues of at least $299 million for the full year 2024, up 54% year-over-year and above its previous guidance range of $284-$290 million. For the fourth quarter, GeneDx anticipates revenues of at least $92 million, representing a 59% increase from the same period last year and a 20% sequential growth.
Additionally, GeneDx achieved profitability, with the company expecting to report adjusted net income for the second consecutive quarter and positive operational cash flow for the first time. The strong financial performance was driven by the growing adoption of GeneDx's genetic testing services as the company continues to expand its product offerings and team.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.